Hydrochlorothiazide

Microzide | HydroDIURIL

FDA ApprovedCardiovascular AgentsDiuretics
FDA: 1959Half-life: 6-15 hoursPregnancy: Category B

Overview

Thiazide diuretic used to treat hypertension and edema by reducing sodium and water reabsorption in the kidneys.

Indications

  • Hypertension
  • Edema (heart failure, hepatic cirrhosis)
  • Nephrolithiasis (calcium stones)
  • Diabetes insipidus (nephrogenic)

Contraindications

  • Anuria
  • Sulfonamide hypersensitivity

Classification

Mechanism of Action

Inhibits sodium-chloride cotransporter in the distal convoluted tubule, increasing sodium and water excretion.

Pharmacodynamics

Reduces blood volume and cardiac output initially, then decreases peripheral vascular resistance with chronic use.

Pharmacokinetics

Absorption
Rapidly absorbed from GI tract. Onset 2 hours, peak 4 hours.
Distribution
Crosses placenta. Distributed to breast milk.
Metabolism
Not metabolized. Excreted unchanged.
Excretion
Renal (>95% unchanged within 24 hours).
Half-life
6-15 hours
Bioavailability
65-75%
Protein Binding
40-68%

Dosage

Typical dosage: 12.5-50mg once daily

Available Forms

  • Tablet
  • Capsule

Side Effects

Common

  • Hypokalemia
  • Hyperuricemia
  • Dizziness
  • Increased urination

Serious

  • Severe electrolyte imbalance
  • Acute renal failure
  • Pancreatitis

Rare

  • Stevens-Johnson syndrome
  • Aplastic anemia

Drug Interactions

major

Thiazides reduce lithium clearance, increasing toxicity risk. Monitor lithium levels closely.

moderate

HCTZ-induced hypokalemia increases risk of digoxin toxicity.

Warnings

Pregnancy

Category B

Toxicity

LD50 >10 g/kg (oral, rat)

Overdose

Symptoms: electrolyte depletion, dehydration, hypotension. Treatment: IV fluids, electrolyte replacement.

References

Looking for patient-friendly information? Visit RemedyDoor for easy-to-read guides about this medication.